given
high
need
absenc
specif
antivir
treatment
diseas
caus
sever
acut
respiratori
syndromeassoci
human
immunodefici
viru
hiv
proteas
inhibitor
consid
therapeut
altern
prezcobixrezolsta
fixeddos
combin
mg
hiv
proteas
inhibitor
darunavir
drv
mg
cobicistat
inhibitor
indic
combin
antiretrovir
agent
treatment
hiv
infect
current
definit
data
safeti
efficaci
drvcobicistat
treatment
vitro
antivir
activ
darunavir
clinic
isol
patient
infect
assess
drv
show
activ
clinic
relev
concentr
ec
remdesivir
use
posit
control
show
potent
antivir
activ
ec
overal
data
support
use
drv
treatment
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
decemb
sever
acut
respiratori
syndromeassoci
coronaviru
emerg
wuhan
hubei
provinc
china
viru
subsequ
identifi
coronaviru
cov
addit
middl
east
respiratori
syndrom
cov
merscov
pass
anim
human
caus
sever
respiratori
ill
march
spread
around
world
declar
global
pandem
given
extent
pandem
urgent
need
identifi
potenti
treatment
diseas
well
develop
vaccin
specif
antivir
treatment
avail
one
avenu
clinic
interest
use
human
immunodefici
viru
hiv
proteas
inhibitor
pi
therapeut
intervent
potenti
hiv
pi
treatment
mainli
base
limit
virolog
clinic
data
hiv
proteas
inhibitor
lopinavir
lowdos
ritonavir
pharmacoenhanc
lpvr
patient
infect
sever
acut
respiratori
syndrom
relat
coronaviru
sarscov
demonstr
vitro
antivir
activ
lpv
clinic
respons
patient
sar
combin
lpvr
ribavirin
examin
patient
treat
lpvr
lower
rate
advers
clinic
outcom
day
follow
onset
symptom
compar
histor
control
howev
recent
data
hospit
adult
sever
confirm
treat
lpvr
addit
standard
care
ventil
oxygen
vasopressor
support
antibiot
renalreplac
therapi
show
signific
improv
time
clinic
improv
mortal
day
compar
standard
care
hiv
pi
darunavir
cobicistat
pharmacoenhanc
drvc
mg
given
oral
daili
food
combin
antiretrovir
agent
approv
experienc
patient
infect
efficaci
safeti
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
profil
boosteddrv
combin
therapi
wellestablish
hiv
set
base
phase
iii
clinic
studi
well
realworld
evid
date
clear
clinic
evid
support
use
drv
boost
either
ritonavir
cobicistat
viral
diseas
hiv
paper
antivir
activ
drv
investig
vitro
model
clinic
relev
concentr
drvc
taken
indic
oncedaili
dose
median
trough
plasma
concentr
drv
ngml
cell
cultur
assay
shown
suitabl
antivir
assay
product
viral
infect
take
place
model
number
sarscov
rna
molecul
increas
continu
infect
indic
viru
undergo
full
replicatori
cycl
remdesivir
nucleotid
analog
initi
develop
ebola
viru
diseas
shown
inhibit
replic
vitro
ec
equal
therefor
use
posit
control
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
human
colon
carcinoma
cell
line
cell
obtain
deutsch
sammlung
von
mikroorganismen
und
zellkulturen
braunschweig
germani
cultur
minim
essenti
medium
mem
supplement
fetal
bovin
serum
fb
contain
penicillin
iuml
streptomycin
gml
co
atmospher
cultur
reagent
purchas
sigma
hamburg
germani
isol
human
sampl
cultur
cell
previous
describ
one
passag
cell
viral
stock
store
prior
use
confluent
layer
cell
cultur
co
atmospher
hour
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
mtt
method
done
two
three
experi
data
analyz
fourparamet
curvefit
doserespons
curv
use
graphpad
prism
version
calcul
ec
concentr
compound
inhibit
infect
base
visual
cpe
score
base
mtt
method
assess
effect
compound
cell
viabil
cell
viabil
measur
confluent
cell
layer
treat
rang
compound
concentr
absenc
viru
use
rotitest
vital
roth
accord
manufactur
instruct
previous
describ
assay
perform
three
time
independ
triplic
cc
cytotox
concentr
compound
reduc
cell
viabil
calcul
doserespons
curv
graphpad
prism
version
use
fourparamet
curvefit
select
index
compound
determin
ratio
cc
ec
gener
silico
dock
use
approach
identifi
subset
molecul
vitro
studi
use
explain
vitro
observ
structur
level
coordin
crystal
structur
main
proteas
retriev
pdb
databas
http
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
quickprep
set
prepar
protein
complex
origin
ligand
remov
gener
dock
set
alter
initi
placement
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
remdesivir
show
strong
antivir
activ
base
visual
score
inhibit
cpe
figur
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
current
effort
manag
pandem
larg
focus
improv
hygien
quarantin
infect
individu
social
distanc
limit
transmiss
develop
vaccin
despit
expedit
effort
develop
vaccin
collabor
effort
screen
compound
discoveri
develop
across
broader
pharmaceut
industri
activ
patient
immedi
need
therapeut
intervent
current
data
therapeut
effect
hiv
proteas
inhibitor
patient
far
comprehens
studi
demonstr
drv
show
vitro
antivir
activ
clinic
relev
concentr
furthermor
structur
analys
use
proteas
structur
consist
data
drv
bind
activ
site
hiv
viru
dimer
aspart
proteas
crystal
structur
proteas
wellelucid
shown
extens
hydrogenbond
network
drv
allow
potent
vitro
activ
ec
valu
nm
proteas
inhibitor
hiv
contrast
main
proteas
cystein
proteas
protein
data
bankcod
sever
dock
pose
found
drv
silico
model
unlik
hiv
pose
show
littl
interact
main
proteas
activ
site
sever
public
describ
silico
dock
experi
main
coronaviru
proteas
specif
focu
includ
drv
although
studi
suggest
drv
candid
investig
promis
dock
result
could
reproduc
silico
dock
studi
discrep
often
result
silico
dock
primarili
use
approach
identifi
subset
molecul
vitro
activ
test
vitro
antivir
activ
drv
found
experi
report
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
studi
remdesivir
demonstr
activ
ec
line
earlier
report
remdesivir
ec
indic
vitro
antivir
assay
use
appropri
assess
antivir
activ
conclus
lack
vitro
antivir
activ
drv
support
use
drv
treatment
henc
use
drv
boost
either
ritonavir
cobicistat
remain
sole
treatment
patient
hiv
infect
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
